The estimated Net Worth of John A Iii Stalfort is at least $2.32 million dollars as of 16 August 2023. John Stalfort owns over 777,778 units of Taysha Gene Therapies stock worth over $2,318,564 and over the last 6 years John sold TSHA stock worth over $0.
Sign up
John Stalfort TSHA stock SEC Form 4 insiders trading
John has made over 5 trades of the Taysha Gene Therapies stock since 2018, according to the Form 4 filled with the SEC. Most recently John bought 777,778 units of TSHA stock worth $700,000 on 16 August 2023.
The largest trade John's ever made was buying 777,778 units of Taysha Gene Therapies stock on 16 August 2023 worth over $700,000. On average, John trades about 135,918 units every 212 days since 2018. As of 16 August 2023 John still owns at least 999,381 units of Taysha Gene Therapies stock.
You can see the complete history of John Stalfort stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's John Stalfort's mailing address?
John's mailing address filed with the SEC is C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247.
Insiders trading at Taysha Gene Therapies
Over the last 4 years, insiders at Taysha Gene Therapies have traded over $3,159,500 worth of Taysha Gene Therapies stock and bought 21,030,825 units worth $24,949,013 . The most active insiders traders include Paul B Manning, John A Iii Stalfort et R.A. Ii Session. On average, Taysha Gene Therapies executives and independent directors trade stock every 44 days with the average trade being worth of $1,947,009. The most recent stock trade was executed by Paul B Manning on 27 June 2024, trading 1,333,333 units of TSHA stock currently worth $2,999,999.
What does Taysha Gene Therapies do?
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
What does Taysha Gene Therapies's logo look like?
Complete history of John Stalfort stock trades at Verrica Pharmaceuticals Inc et Taysha Gene Therapies
Taysha Gene Therapies executives and stock owners
Taysha Gene Therapies executives and other stock owners filed with the SEC include:
-
Kamran Alam CPA, M.B.A.,
Chief Financial Officer -
R. A. Session II,
Founder, Pres, CEO & Director -
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M,
Chief Medical Officer and Head of R&D -
Dr. Claire Aldridge Ph.D.,
Sr. VP & Chief of Staff and Bus. Operations -
Emily McGinnis M.P.H.,
Chief Patient Officer & Head of Gov. Affairs -
Tracy M. Porter,
Chief People Officer -
Timothy J. Douros J.D.,
Chief Legal Officer & Corp. Sec. -
Dr. Kimberly Lee D.O.,
Sr. VP of Corp. Communications & Investor Relations -
Jim Rouse,
Chief Information Officer -
Frederick Porter Ph.D.,
Chief Technical Officer -
Paul B Manning,
-
Laura Sepp Lorenzino,
-
R.A. Ii Session,
-
Sean P. Nolan,
Chief Executive Officer -
Suyash Prasad,
CMO and Head of R&D -
Kathleen Reape,
Director -
John A Iii Stalfort,
-
Alison S Long,
-
Phillip B. Donenberg,